• Resize Text
    • Small Text
    • Medium Text
    • Large Text
    • Connect

Rosemont Pharmaceuticals unveils plans to expand in the USA

 

The UK based liquids specialist, Rosemont Pharmaceuticals (Rosemont) has announced it is on the lookout for merger and acquisition (M & A) opportunities in the USA as part of a drive to expand the business internationally.

The company already provides lifesaving pharmaceuticals to the UK and overseas markets but its chief executive, Howard Taylor, has now made public his plans to drive the business forward – particularly in North American markets including Canada. France and Germany have also been highlighted as attractive propositions.

Rosemont was acquired by the private equity firm Inflexion in 2020 and has increasingly been looking to expand outside of the UK and into other markets since then. Different international regulatory strategies will give the business the opportunity to provide more offerings from the company’s portfolio of 130 oral liquid medicines.

Mr Taylor said the acquisition by Inflexion had provided a very supportive backer for the business and which had allowed it to further invest in developing the liquid medicines portfolio but also move beyond that. The annual turnover now stands at $140m.

He said: “Until now we’ve been seen as a UK centred business but look ahead four or five years and you’ll see we will have a much more global footprint. Europe will still be our main market but our move and our growth trajectory towards international expansion has been a conscious decision.”

He said moving forward involved partnering more with CDMOs (contract development and manufacturing organisations) and buying in technologies to advance the development, licensing, production and commercial sales of its products.

“While the majority of our effort is still around our core business, our own development pipeline and our current partnerships, M and A is a definite strategy. We want to move into new areas, work with the US Food and Drug Administration and ultimately benefit more patients with dysphagia and swallowing difficulties.”

 

 

ROS000066-003 January 2024

Rosemont Pharmaceuticals unveils plans to expand in the USA

 

The UK based liquids specialist, Rosemont Pharmaceuticals (Rosemont) has announced it is on the lookout for merger and acquisition (M & A) opportunities in the USA as part of a drive to expand the business internationally.

The company already provides lifesaving pharmaceuticals to the UK and overseas markets but its chief executive, Howard Taylor, has now made public his plans to drive the business forward – particularly in North American markets including Canada. France and Germany have also been highlighted as attractive propositions.

Rosemont was acquired by the private equity firm Inflexion in 2020 and has increasingly been looking to expand outside of the UK and into other markets since then. Different international regulatory strategies will give the business the opportunity to provide more offerings from the company’s portfolio of 130 oral liquid medicines.

Mr Taylor said the acquisition by Inflexion had provided a very supportive backer for the business and which had allowed it to further invest in developing the liquid medicines portfolio but also move beyond that. The annual turnover now stands at $140m.

He said: “Until now we’ve been seen as a UK centred business but look ahead four or five years and you’ll see we will have a much more global footprint. Europe will still be our main market but our move and our growth trajectory towards international expansion has been a conscious decision.”

He said moving forward involved partnering more with CDMOs (contract development and manufacturing organisations) and buying in technologies to advance the development, licensing, production and commercial sales of its products.

“While the majority of our effort is still around our core business, our own development pipeline and our current partnerships, M and A is a definite strategy. We want to move into new areas, work with the US Food and Drug Administration and ultimately benefit more patients with dysphagia and swallowing difficulties.”

 

 

ROS000066-003 January 2024

Rosemont Pharmaceuticals - Rosemont are Finalists for an Operational Excellence Award

We are thrilled to announce that we’re finalists at the Pharma Industry Awards 2023. We’ve been shortlisted for the Operational Excellence Award category.

Rosemont has grown quickly in recent years. We are now a £100m revenue business with a 280-strong team. Our business recently opened a new state-of-the-art Innovation Centre, to fast-track plans to expand our existing portfolio of over 130 oral liquid medicines.

The Pharma Industry Awards identify and celebrate the most original and innovative companies and individuals that demonstrate excellence in the UK pharma industry. The awards recognise companies from a variety of different sectors, from drug development to plant production designers.

The Operational Excellence Award acknowledges companies that have used operational excellence as a critical driver to ensure processing and manufacturing efficiency and excellence. We earned our nomination by showcasing our operational efficiency, innovation, quality standards and budgetary efficiency.

Since 2020, Rosemont has increased sales by 231% and our workforce by 45%. We’ve made significant investments in manufacturing facilities, resulting in increased capacity and operational efficiencies.

Our company consistently achieves a high level of customer service, with a 98% ‘On Time in Full’ rate. The company has also implemented inventive measures to reduce downtime and changeover times, enhancing efficiency and productivity.

In addition, we’ve shown a commitment to innovation through upgrades in equipment and environmental investments. The multi-million-pound investment in our newly opened Innovation Centre further supports our company’s research and development efforts.

Rosemont’s dedication to operational excellence, quality standards, and sustainability has led to us establishing our position as a prominent figure in the pharmaceutical industry. By demonstrating these values to the judging panel, this has secured us our finalist nomination in the Operational Excellence category.

Read about our other Pharma Industry Awards nomination: Pharma Research Centre of the Year

The full shortlist of the Pharma Industry Awards finalists is available here: Shortlist

The awards ceremony will take place on Thursday 28th September 2023 at the Hilton Hotel, Deansgate, Manchester.

ROS000036-016,  DOP August 2023

Rosemont Pharmaceuticals unveils plans to expand in the USA

 

The UK based liquids specialist, Rosemont Pharmaceuticals (Rosemont) has announced it is on the lookout for merger and acquisition (M & A) opportunities in the USA as part of a drive to expand the business internationally.

The company already provides lifesaving pharmaceuticals to the UK and overseas markets but its chief executive, Howard Taylor, has now made public his plans to drive the business forward – particularly in North American markets including Canada. France and Germany have also been highlighted as attractive propositions.

Rosemont was acquired by the private equity firm Inflexion in 2020 and has increasingly been looking to expand outside of the UK and into other markets since then. Different international regulatory strategies will give the business the opportunity to provide more offerings from the company’s portfolio of 130 oral liquid medicines.

Mr Taylor said the acquisition by Inflexion had provided a very supportive backer for the business and which had allowed it to further invest in developing the liquid medicines portfolio but also move beyond that. The annual turnover now stands at $140m.

He said: “Until now we’ve been seen as a UK centred business but look ahead four or five years and you’ll see we will have a much more global footprint. Europe will still be our main market but our move and our growth trajectory towards international expansion has been a conscious decision.”

He said moving forward involved partnering more with CDMOs (contract development and manufacturing organisations) and buying in technologies to advance the development, licensing, production and commercial sales of its products.

“While the majority of our effort is still around our core business, our own development pipeline and our current partnerships, M and A is a definite strategy. We want to move into new areas, work with the US Food and Drug Administration and ultimately benefit more patients with dysphagia and swallowing difficulties.”

 

 

ROS000066-003 January 2024

Rosemont Pharmaceuticals - Rosemont are Finalists for an Operational Excellence Award

We are thrilled to announce that we’re finalists at the Pharma Industry Awards 2023. We’ve been shortlisted for the Operational Excellence Award category.

Rosemont has grown quickly in recent years. We are now a £100m revenue business with a 280-strong team. Our business recently opened a new state-of-the-art Innovation Centre, to fast-track plans to expand our existing portfolio of over 130 oral liquid medicines.

The Pharma Industry Awards identify and celebrate the most original and innovative companies and individuals that demonstrate excellence in the UK pharma industry. The awards recognise companies from a variety of different sectors, from drug development to plant production designers.

The Operational Excellence Award acknowledges companies that have used operational excellence as a critical driver to ensure processing and manufacturing efficiency and excellence. We earned our nomination by showcasing our operational efficiency, innovation, quality standards and budgetary efficiency.

Since 2020, Rosemont has increased sales by 231% and our workforce by 45%. We’ve made significant investments in manufacturing facilities, resulting in increased capacity and operational efficiencies.

Our company consistently achieves a high level of customer service, with a 98% ‘On Time in Full’ rate. The company has also implemented inventive measures to reduce downtime and changeover times, enhancing efficiency and productivity.

In addition, we’ve shown a commitment to innovation through upgrades in equipment and environmental investments. The multi-million-pound investment in our newly opened Innovation Centre further supports our company’s research and development efforts.

Rosemont’s dedication to operational excellence, quality standards, and sustainability has led to us establishing our position as a prominent figure in the pharmaceutical industry. By demonstrating these values to the judging panel, this has secured us our finalist nomination in the Operational Excellence category.

Read about our other Pharma Industry Awards nomination: Pharma Research Centre of the Year

The full shortlist of the Pharma Industry Awards finalists is available here: Shortlist

The awards ceremony will take place on Thursday 28th September 2023 at the Hilton Hotel, Deansgate, Manchester.

ROS000036-016,  DOP August 2023

Rosemont Pharmaceuticals unveils plans to expand in the USA

 

The UK based liquids specialist, Rosemont Pharmaceuticals (Rosemont) has announced it is on the lookout for merger and acquisition (M & A) opportunities in the USA as part of a drive to expand the business internationally.

The company already provides lifesaving pharmaceuticals to the UK and overseas markets but its chief executive, Howard Taylor, has now made public his plans to drive the business forward – particularly in North American markets including Canada. France and Germany have also been highlighted as attractive propositions.

Rosemont was acquired by the private equity firm Inflexion in 2020 and has increasingly been looking to expand outside of the UK and into other markets since then. Different international regulatory strategies will give the business the opportunity to provide more offerings from the company’s portfolio of 130 oral liquid medicines.

Mr Taylor said the acquisition by Inflexion had provided a very supportive backer for the business and which had allowed it to further invest in developing the liquid medicines portfolio but also move beyond that. The annual turnover now stands at $140m.

He said: “Until now we’ve been seen as a UK centred business but look ahead four or five years and you’ll see we will have a much more global footprint. Europe will still be our main market but our move and our growth trajectory towards international expansion has been a conscious decision.”

He said moving forward involved partnering more with CDMOs (contract development and manufacturing organisations) and buying in technologies to advance the development, licensing, production and commercial sales of its products.

“While the majority of our effort is still around our core business, our own development pipeline and our current partnerships, M and A is a definite strategy. We want to move into new areas, work with the US Food and Drug Administration and ultimately benefit more patients with dysphagia and swallowing difficulties.”

 

 

ROS000066-003 January 2024

Rosemont Pharmaceuticals - Rosemont are Finalists for an Operational Excellence Award

We are thrilled to announce that we’re finalists at the Pharma Industry Awards 2023. We’ve been shortlisted for the Operational Excellence Award category.

Rosemont has grown quickly in recent years. We are now a £100m revenue business with a 280-strong team. Our business recently opened a new state-of-the-art Innovation Centre, to fast-track plans to expand our existing portfolio of over 130 oral liquid medicines.

The Pharma Industry Awards identify and celebrate the most original and innovative companies and individuals that demonstrate excellence in the UK pharma industry. The awards recognise companies from a variety of different sectors, from drug development to plant production designers.

The Operational Excellence Award acknowledges companies that have used operational excellence as a critical driver to ensure processing and manufacturing efficiency and excellence. We earned our nomination by showcasing our operational efficiency, innovation, quality standards and budgetary efficiency.

Since 2020, Rosemont has increased sales by 231% and our workforce by 45%. We’ve made significant investments in manufacturing facilities, resulting in increased capacity and operational efficiencies.

Our company consistently achieves a high level of customer service, with a 98% ‘On Time in Full’ rate. The company has also implemented inventive measures to reduce downtime and changeover times, enhancing efficiency and productivity.

In addition, we’ve shown a commitment to innovation through upgrades in equipment and environmental investments. The multi-million-pound investment in our newly opened Innovation Centre further supports our company’s research and development efforts.

Rosemont’s dedication to operational excellence, quality standards, and sustainability has led to us establishing our position as a prominent figure in the pharmaceutical industry. By demonstrating these values to the judging panel, this has secured us our finalist nomination in the Operational Excellence category.

Read about our other Pharma Industry Awards nomination: Pharma Research Centre of the Year

The full shortlist of the Pharma Industry Awards finalists is available here: Shortlist

The awards ceremony will take place on Thursday 28th September 2023 at the Hilton Hotel, Deansgate, Manchester.

ROS000036-016,  DOP August 2023

Rosemont Pharmaceuticals unveils plans to expand in the USA

 

The UK based liquids specialist, Rosemont Pharmaceuticals (Rosemont) has announced it is on the lookout for merger and acquisition (M & A) opportunities in the USA as part of a drive to expand the business internationally.

The company already provides lifesaving pharmaceuticals to the UK and overseas markets but its chief executive, Howard Taylor, has now made public his plans to drive the business forward – particularly in North American markets including Canada. France and Germany have also been highlighted as attractive propositions.

Rosemont was acquired by the private equity firm Inflexion in 2020 and has increasingly been looking to expand outside of the UK and into other markets since then. Different international regulatory strategies will give the business the opportunity to provide more offerings from the company’s portfolio of 130 oral liquid medicines.

Mr Taylor said the acquisition by Inflexion had provided a very supportive backer for the business and which had allowed it to further invest in developing the liquid medicines portfolio but also move beyond that. The annual turnover now stands at $140m.

He said: “Until now we’ve been seen as a UK centred business but look ahead four or five years and you’ll see we will have a much more global footprint. Europe will still be our main market but our move and our growth trajectory towards international expansion has been a conscious decision.”

He said moving forward involved partnering more with CDMOs (contract development and manufacturing organisations) and buying in technologies to advance the development, licensing, production and commercial sales of its products.

“While the majority of our effort is still around our core business, our own development pipeline and our current partnerships, M and A is a definite strategy. We want to move into new areas, work with the US Food and Drug Administration and ultimately benefit more patients with dysphagia and swallowing difficulties.”

 

 

ROS000066-003 January 2024

Rosemont Pharmaceuticals - Rosemont are Finalists for an Operational Excellence Award

We are thrilled to announce that we’re finalists at the Pharma Industry Awards 2023. We’ve been shortlisted for the Operational Excellence Award category.

Rosemont has grown quickly in recent years. We are now a £100m revenue business with a 280-strong team. Our business recently opened a new state-of-the-art Innovation Centre, to fast-track plans to expand our existing portfolio of over 130 oral liquid medicines.

The Pharma Industry Awards identify and celebrate the most original and innovative companies and individuals that demonstrate excellence in the UK pharma industry. The awards recognise companies from a variety of different sectors, from drug development to plant production designers.

The Operational Excellence Award acknowledges companies that have used operational excellence as a critical driver to ensure processing and manufacturing efficiency and excellence. We earned our nomination by showcasing our operational efficiency, innovation, quality standards and budgetary efficiency.

Since 2020, Rosemont has increased sales by 231% and our workforce by 45%. We’ve made significant investments in manufacturing facilities, resulting in increased capacity and operational efficiencies.

Our company consistently achieves a high level of customer service, with a 98% ‘On Time in Full’ rate. The company has also implemented inventive measures to reduce downtime and changeover times, enhancing efficiency and productivity.

In addition, we’ve shown a commitment to innovation through upgrades in equipment and environmental investments. The multi-million-pound investment in our newly opened Innovation Centre further supports our company’s research and development efforts.

Rosemont’s dedication to operational excellence, quality standards, and sustainability has led to us establishing our position as a prominent figure in the pharmaceutical industry. By demonstrating these values to the judging panel, this has secured us our finalist nomination in the Operational Excellence category.

Read about our other Pharma Industry Awards nomination: Pharma Research Centre of the Year

The full shortlist of the Pharma Industry Awards finalists is available here: Shortlist

The awards ceremony will take place on Thursday 28th September 2023 at the Hilton Hotel, Deansgate, Manchester.

ROS000036-016,  DOP August 2023

Rosemont Pharmaceuticals unveils plans to expand in the USA

 

The UK based liquids specialist, Rosemont Pharmaceuticals (Rosemont) has announced it is on the lookout for merger and acquisition (M & A) opportunities in the USA as part of a drive to expand the business internationally.

The company already provides lifesaving pharmaceuticals to the UK and overseas markets but its chief executive, Howard Taylor, has now made public his plans to drive the business forward – particularly in North American markets including Canada. France and Germany have also been highlighted as attractive propositions.

Rosemont was acquired by the private equity firm Inflexion in 2020 and has increasingly been looking to expand outside of the UK and into other markets since then. Different international regulatory strategies will give the business the opportunity to provide more offerings from the company’s portfolio of 130 oral liquid medicines.

Mr Taylor said the acquisition by Inflexion had provided a very supportive backer for the business and which had allowed it to further invest in developing the liquid medicines portfolio but also move beyond that. The annual turnover now stands at $140m.

He said: “Until now we’ve been seen as a UK centred business but look ahead four or five years and you’ll see we will have a much more global footprint. Europe will still be our main market but our move and our growth trajectory towards international expansion has been a conscious decision.”

He said moving forward involved partnering more with CDMOs (contract development and manufacturing organisations) and buying in technologies to advance the development, licensing, production and commercial sales of its products.

“While the majority of our effort is still around our core business, our own development pipeline and our current partnerships, M and A is a definite strategy. We want to move into new areas, work with the US Food and Drug Administration and ultimately benefit more patients with dysphagia and swallowing difficulties.”

 

 

ROS000066-003 January 2024

Rosemont Pharmaceuticals - Rosemont are Finalists for an Operational Excellence Award

We are thrilled to announce that we’re finalists at the Pharma Industry Awards 2023. We’ve been shortlisted for the Operational Excellence Award category.

Rosemont has grown quickly in recent years. We are now a £100m revenue business with a 280-strong team. Our business recently opened a new state-of-the-art Innovation Centre, to fast-track plans to expand our existing portfolio of over 130 oral liquid medicines.

The Pharma Industry Awards identify and celebrate the most original and innovative companies and individuals that demonstrate excellence in the UK pharma industry. The awards recognise companies from a variety of different sectors, from drug development to plant production designers.

The Operational Excellence Award acknowledges companies that have used operational excellence as a critical driver to ensure processing and manufacturing efficiency and excellence. We earned our nomination by showcasing our operational efficiency, innovation, quality standards and budgetary efficiency.

Since 2020, Rosemont has increased sales by 231% and our workforce by 45%. We’ve made significant investments in manufacturing facilities, resulting in increased capacity and operational efficiencies.

Our company consistently achieves a high level of customer service, with a 98% ‘On Time in Full’ rate. The company has also implemented inventive measures to reduce downtime and changeover times, enhancing efficiency and productivity.

In addition, we’ve shown a commitment to innovation through upgrades in equipment and environmental investments. The multi-million-pound investment in our newly opened Innovation Centre further supports our company’s research and development efforts.

Rosemont’s dedication to operational excellence, quality standards, and sustainability has led to us establishing our position as a prominent figure in the pharmaceutical industry. By demonstrating these values to the judging panel, this has secured us our finalist nomination in the Operational Excellence category.

Read about our other Pharma Industry Awards nomination: Pharma Research Centre of the Year

The full shortlist of the Pharma Industry Awards finalists is available here: Shortlist

The awards ceremony will take place on Thursday 28th September 2023 at the Hilton Hotel, Deansgate, Manchester.

ROS000036-016,  DOP August 2023

Rosemont Pharmaceuticals unveils plans to expand in the USA

 

The UK based liquids specialist, Rosemont Pharmaceuticals (Rosemont) has announced it is on the lookout for merger and acquisition (M & A) opportunities in the USA as part of a drive to expand the business internationally.

The company already provides lifesaving pharmaceuticals to the UK and overseas markets but its chief executive, Howard Taylor, has now made public his plans to drive the business forward – particularly in North American markets including Canada. France and Germany have also been highlighted as attractive propositions.

Rosemont was acquired by the private equity firm Inflexion in 2020 and has increasingly been looking to expand outside of the UK and into other markets since then. Different international regulatory strategies will give the business the opportunity to provide more offerings from the company’s portfolio of 130 oral liquid medicines.

Mr Taylor said the acquisition by Inflexion had provided a very supportive backer for the business and which had allowed it to further invest in developing the liquid medicines portfolio but also move beyond that. The annual turnover now stands at $140m.

He said: “Until now we’ve been seen as a UK centred business but look ahead four or five years and you’ll see we will have a much more global footprint. Europe will still be our main market but our move and our growth trajectory towards international expansion has been a conscious decision.”

He said moving forward involved partnering more with CDMOs (contract development and manufacturing organisations) and buying in technologies to advance the development, licensing, production and commercial sales of its products.

“While the majority of our effort is still around our core business, our own development pipeline and our current partnerships, M and A is a definite strategy. We want to move into new areas, work with the US Food and Drug Administration and ultimately benefit more patients with dysphagia and swallowing difficulties.”

 

 

ROS000066-003 January 2024

Rosemont Pharmaceuticals - Rosemont are Finalists for an Operational Excellence Award

We are thrilled to announce that we’re finalists at the Pharma Industry Awards 2023. We’ve been shortlisted for the Operational Excellence Award category.

Rosemont has grown quickly in recent years. We are now a £100m revenue business with a 280-strong team. Our business recently opened a new state-of-the-art Innovation Centre, to fast-track plans to expand our existing portfolio of over 130 oral liquid medicines.

The Pharma Industry Awards identify and celebrate the most original and innovative companies and individuals that demonstrate excellence in the UK pharma industry. The awards recognise companies from a variety of different sectors, from drug development to plant production designers.

The Operational Excellence Award acknowledges companies that have used operational excellence as a critical driver to ensure processing and manufacturing efficiency and excellence. We earned our nomination by showcasing our operational efficiency, innovation, quality standards and budgetary efficiency.

Since 2020, Rosemont has increased sales by 231% and our workforce by 45%. We’ve made significant investments in manufacturing facilities, resulting in increased capacity and operational efficiencies.

Our company consistently achieves a high level of customer service, with a 98% ‘On Time in Full’ rate. The company has also implemented inventive measures to reduce downtime and changeover times, enhancing efficiency and productivity.

In addition, we’ve shown a commitment to innovation through upgrades in equipment and environmental investments. The multi-million-pound investment in our newly opened Innovation Centre further supports our company’s research and development efforts.

Rosemont’s dedication to operational excellence, quality standards, and sustainability has led to us establishing our position as a prominent figure in the pharmaceutical industry. By demonstrating these values to the judging panel, this has secured us our finalist nomination in the Operational Excellence category.

Read about our other Pharma Industry Awards nomination: Pharma Research Centre of the Year

The full shortlist of the Pharma Industry Awards finalists is available here: Shortlist

The awards ceremony will take place on Thursday 28th September 2023 at the Hilton Hotel, Deansgate, Manchester.

ROS000036-016,  DOP August 2023

Rosemont Pharmaceuticals unveils plans to expand in the USA

 

The UK based liquids specialist, Rosemont Pharmaceuticals (Rosemont) has announced it is on the lookout for merger and acquisition (M & A) opportunities in the USA as part of a drive to expand the business internationally.

The company already provides lifesaving pharmaceuticals to the UK and overseas markets but its chief executive, Howard Taylor, has now made public his plans to drive the business forward – particularly in North American markets including Canada. France and Germany have also been highlighted as attractive propositions.

Rosemont was acquired by the private equity firm Inflexion in 2020 and has increasingly been looking to expand outside of the UK and into other markets since then. Different international regulatory strategies will give the business the opportunity to provide more offerings from the company’s portfolio of 130 oral liquid medicines.

Mr Taylor said the acquisition by Inflexion had provided a very supportive backer for the business and which had allowed it to further invest in developing the liquid medicines portfolio but also move beyond that. The annual turnover now stands at $140m.

He said: “Until now we’ve been seen as a UK centred business but look ahead four or five years and you’ll see we will have a much more global footprint. Europe will still be our main market but our move and our growth trajectory towards international expansion has been a conscious decision.”

He said moving forward involved partnering more with CDMOs (contract development and manufacturing organisations) and buying in technologies to advance the development, licensing, production and commercial sales of its products.

“While the majority of our effort is still around our core business, our own development pipeline and our current partnerships, M and A is a definite strategy. We want to move into new areas, work with the US Food and Drug Administration and ultimately benefit more patients with dysphagia and swallowing difficulties.”

 

 

ROS000066-003 January 2024

Rosemont Pharmaceuticals - Rosemont are Finalists for an Operational Excellence Award

We are thrilled to announce that we’re finalists at the Pharma Industry Awards 2023. We’ve been shortlisted for the Operational Excellence Award category.

Rosemont has grown quickly in recent years. We are now a £100m revenue business with a 280-strong team. Our business recently opened a new state-of-the-art Innovation Centre, to fast-track plans to expand our existing portfolio of over 130 oral liquid medicines.

The Pharma Industry Awards identify and celebrate the most original and innovative companies and individuals that demonstrate excellence in the UK pharma industry. The awards recognise companies from a variety of different sectors, from drug development to plant production designers.

The Operational Excellence Award acknowledges companies that have used operational excellence as a critical driver to ensure processing and manufacturing efficiency and excellence. We earned our nomination by showcasing our operational efficiency, innovation, quality standards and budgetary efficiency.

Since 2020, Rosemont has increased sales by 231% and our workforce by 45%. We’ve made significant investments in manufacturing facilities, resulting in increased capacity and operational efficiencies.

Our company consistently achieves a high level of customer service, with a 98% ‘On Time in Full’ rate. The company has also implemented inventive measures to reduce downtime and changeover times, enhancing efficiency and productivity.

In addition, we’ve shown a commitment to innovation through upgrades in equipment and environmental investments. The multi-million-pound investment in our newly opened Innovation Centre further supports our company’s research and development efforts.

Rosemont’s dedication to operational excellence, quality standards, and sustainability has led to us establishing our position as a prominent figure in the pharmaceutical industry. By demonstrating these values to the judging panel, this has secured us our finalist nomination in the Operational Excellence category.

Read about our other Pharma Industry Awards nomination: Pharma Research Centre of the Year

The full shortlist of the Pharma Industry Awards finalists is available here: Shortlist

The awards ceremony will take place on Thursday 28th September 2023 at the Hilton Hotel, Deansgate, Manchester.

ROS000036-016,  DOP August 2023